Greene v. Abbott Laboratories

148 A.D.2d 403, 539 N.Y.S.2d 351, 1989 N.Y. App. Div. LEXIS 4174
CourtAppellate Division of the Supreme Court of the State of New York
DecidedMarch 30, 1989
StatusPublished
Cited by7 cases

This text of 148 A.D.2d 403 (Greene v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering Appellate Division of the Supreme Court of the State of New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Greene v. Abbott Laboratories, 148 A.D.2d 403, 539 N.Y.S.2d 351, 1989 N.Y. App. Div. LEXIS 4174 (N.Y. Ct. App. 1989).

Opinion

Order, Supreme Court, New York County (Ira Gammerman, J.), entered February 2, 1988, which granted the motion of defendants Merck, Abbott Laboratories, the Upjohn Company, E. R. Squibb & Sons, Inc., and Eli Lilly & Co. to dismiss the second, fourth and sixth causes of action of the complaint for wrongful death as barred by the Statute of Limitations, and the judgment of the same court entered thereon on March 3, 1988 are unanimously affirmed, without costs.

On March 9, 1969, one month after her 18th birthday, plaintiffs intestate, his daughter Susan, died allegedly from a type of cancer which had developed three years before, brought on because her mother had taken the drug diethylstilbestrol (DES) while pregnant with Susan in 1950 and 1951. Defendants-respondents are all manufacturers of this drug.

Plaintiff, as Susan’s administrator, commenced this action in June and July 1987 asserting three causes of action for personal injury and three causes of action for wrongful death. We are only concerned with the latter here.

The IAS court granted respondents’ motion to dismiss the wrongful death causes of action on the ground that they are barred by the applicable Statute of Limitations. At issue on this appeal is whether the so-called one-year "revival” statute for injury arising from ingestion of five toxic substances (including DES) (L 1986, ch 682, § 4) operates in this action so as to resurrect plaintiffs otherwise time-barred wrongful death claims or, in the alternative, whether, by virtue of respondents’ wrongful conduct, they are estopped from raising this defense.

The revival statute provides: "[E]very action for personal injury, injury to property or death caused by the latent effects of exposure to diethylstilbestrol [and four other substances] upon or within the body or upon or within property which is barred as of the effective date of this act or which was dismissed prior to the effective date of this act solely because [404]*404the applicable period of limitations has or had expired is hereby revived and an action thereon may be commenced provided such action is commenced within one year from the effective date of this act;

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Pfohl Bros. Landfill Litigation
26 F. Supp. 2d 512 (W.D. New York, 1998)
In re New York County Des Litigation
142 F.R.D. 58 (E.D. New York, 1992)
Monte v. National Gypsum Company
921 F.2d 405 (Second Circuit, 1990)
Monte v. National Gypsum Co.
921 F.2d 405 (Second Circuit, 1990)
In re the Arbitration between Allstate Insurance & Michel
164 A.D.2d 776 (Appellate Division of the Supreme Court of New York, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
148 A.D.2d 403, 539 N.Y.S.2d 351, 1989 N.Y. App. Div. LEXIS 4174, Counsel Stack Legal Research, https://law.counselstack.com/opinion/greene-v-abbott-laboratories-nyappdiv-1989.